(Challenger 350 interior image via Bombardier Inc.)
Much like that Will Rogers quote that is all too real, even these days … The world is trying to get as close to a “pre-pandemic” norm as it can and nowhere is this movement more evident than in the aviation industry.
Air Canada Inc. (TSX: AC, Forum) recently unveiled additional details of its planned international schedule for summer 2021, which includes the resumption of
17 routes and 11 destinations across the world from its hubs. The airline also announced that it is resuming its service between Calgary and Frankfurt, as of August 1st, 2021, up to four times weekly, and is also offering for the first time a unique non-stop service from Montreal to Cairo, Egypt, three times weekly.
This is good news for Air Canada and right on time, as its leadership team is set to present its
Q2 2021 financial results July 23rd, 2021. This is probably the first time in a long time that anyone has used “Air Canada” and “on time” in the same sentence.
Meanwhile, Bombardier Inc. (TSX: BBD, Forum) just announced the recent delivery of a brand-new
Challenger 350 business jet (pictured at the top of this page).
Executive charter, aircraft management, and special mission company based in Norway; Sundt Air will manage the Challenger 350 business jet out of Oslo. Sundt Air is also the largest operator of business jets in Norway.
The Challenger 350 is distinct in aviation, as it allows passengers to remain comfortable, productive, and well-rested as more people seek out safe and flexible alternative ways to travel, says Bombarider’s Senior Vice President, Sales, New Aircraft, Peter Likoray.
Global provider of clean energy solutions,
Xebec Adsorption Inc. (TSX-V: XBC, Forum) has agreed to manufacture
BGX Biostream units for a leading US renewable natural gas dairy farm developer.
Starting at a list price of $1.5 million (USD), Xebec's Biostream solution generates renewable natural gas from biogas, which comes from municipal landfills, wastewater treatment plants and anaerobic digesters processing agricultural and industrial organic waste.
The master service agreement supports the order of an initial 18 units with the potential for additional orders under the same agreement. This is Xebec's largest Biostream order to date and the largest ever awarded in North America for dairy farm biogas upgrading projects.
As a result of the agreement and additional expected orders, Xebec has started production on 30 Biostream units for delivery over the next year.
According to the American Biogas Council, approximately 8,574 dairy, poultry and swine farms are primed for biogas and renewable natural gas production.
As of May 2021, there are 333 operational and under-construction digester projects that accept livestock manure, according to the EPA AgSTAR project database. Approximately 82% of the projects are at dairy farms. Of the 333 projects, approximately 98 of them are producing renewable natural gas for the local CNG transportation market or for injection into the local pipeline.
Renewable natural gas from dairy manure has a negative carbon intensity score of -100 to -400, according to the California Air Resources Board, compared to 102 and 34 to 75 for diesel and corn ethanol, respectively.
Progressive medical diagnostic and device technology company
Therma Bright Inc. (TSX-V: THRM, Forum) has confirmed that its AcuVid COVID-19 Rapid Antigen Saliva Test
successfully detected the COVID-19 Delta B.1.617.2 variant.
The AcuVid / Delta variant study was completed at the company's Brazilian clinical study partner's lab location at the Federal University of Minas Gerais.
Ever since the SARS-CoV-2 Coronavirus became a global pandemic in 2020, new variants have emerged, and the scientific community has worked to evaluate each strain and its impact on our health.
The Delta B.1.617.2 variant has now become the dominant COVID-19 strain around the world. The World Health Organization has urged fully vaccinated people to continue wearing masks due to this new variant strain.
On June 24th Therma Bright and its partners initiated the Delta variant study. The study focused on ensuring Therma Bright's AcuVid COVID-19 Rapid Antigen Saliva Test would detect the ever-growing list of mutations from the original SARS-CoV-2 Novel Coronavirus. To date, Therma Bright's AcuVid Rapid Antigen Saliva Test has successfully detected not only the original virus but the P.1 and P.2 variants discovered in Brazil, the B.1.1.7 variant from the UK and now the highly contagious Delta B.1.617.2 variant from India.
Therma Bright CEO Rob Fia explained that that the spread of the COVID-19 virus is believed can be mitigated by early detection through serial testing of individual people.
“Many antigen test manufacturers believe their solutions will be able to detect these new, mutating variants. At Therma Bright, we have gone that extra mile to conduct the critical research to validate and ensure our AcuVid COVID-19 Rapid Antigen Saliva Test does indeed successfully detect not only the original COVID-19 virus, but all major variants, including this fast moving and most contagious Delta strain.”
What the "Buzz"
Our Bullboards have up to 2 Million pageviews a day. Get the inside scoop on conversations around the most significant trends and stock appreciations in our weekly wrap up.
Get "Buzz on the Bullboards" delivered to your inbox every Thursday!
Buzz on the Bullboards | Sign Up Here
HEXO Corp. (TSX: HEXO, Forum) updated shareholders this week on its move to acquire Canada’s largest privately-owned licensed producer –
Redecan. HEXO has now obtained and will be shortly filing the recently completed audited consolidated financial statements of Redecan for the financial year ended December 31st, 2020, and the unaudited interim financial statements for the first quarter ended March 31st, 2021.
Key Financial Highlights:
Revenue, net of excise duties of $73.6M for F20 and $24.7 million in Q1 F21, representing an increase of 146% over Q1 F20
Unadjusted EBITDA of $28.9M for F20 and $12.4M for Q1 F21, reconciled as such:
|
Q1 F21 |
F20 |
| Net Earnings |
6,913,624 |
11,624,161 |
| Add back: |
|
|
| Amortization |
4,216,528 |
12,174,795 |
| Impairment loss on property, plant and equipment |
37,235 |
588,593 |
| Provision for income taxes |
1,230,000 |
4,499,595 |
| Unadjusted EBITDA |
12,397,387 |
28,887,144 |
- Income from operations were $8.3 million (CAN) and net earnings of $6.9 million (CAN) in Q1 fiscal 2021
- Income from operations were $16.7 million (CAN) and net earnings of $11.6 million in fiscal year 2020
This brings us to our Investor Pulse Poll question of the week – as an investor, what do you focus on more, a company’s products and services (however cutting edge and amazing they may be) or its overall stock performance? Let us know your thoughts by clicking the image below to cast your vote.
(Click image to vote.)
Last week, we asked for your thoughts on the latest trends with the energy sector. Do you think it is going to boom over the next half of the year, or will it fall farther? Here is what those polled last week said.
We turn back to the Buzz with s newcomer to the Health Care Top 6,
Quipt Home Medical Corp. (TSX-V: QIPT, Forum) has already been making impressive moves.
Operating in the home medical equipment industry, Quipt is focused on end-to-end respiratory care. As a result of the pandemic, home medical device requirements surged and Quipt Home Medical met the demand with its innovative subscription services and its novel platform technology, including the Durable Medical Equipment (
DME) delivery process. Quipt Home Medical, is headquartered in Kentucky and in addition to supplying in-home monitoring equipment, provides daily and ambulatory aides, oxygen therapy, sleep apnea treatment, home ventilation, and respiratory equipment rentals across North America.
QIPT recently acquired three separate entities with combined operations in California, Missouri, Arkansas, and Mississippi, reporting combined unaudited trailing 12-month annual revenues of approximately $5.5 million (USD), and Adjusted EBITDA of $550,000 (USD) prior to integration.
New Found Gold (TSX-V: NFG, Forum) has come back with good news from its Beatons Creek conglomerate gold project in Nullagine, Western Australia.
Mining and processing rates continued to increase, with
232 kt gold-bearing conglomerate material mined in June (Q2 2021 – 477 kt gold-bearing conglomerate material mined) and 134 kt gold-bearing conglomerate material processed in June (Q2 – 366 kt gold-bearing conglomerate material processed). NFG logged record gold production of 5,898 oz Au in June, a 16.5% increase over May (Q2 2021 – 14,890 oz Au). The company’s June revenue of $11.9 million (CAD) represents an 11.4% increase over May (Q2 2021 – $31.7 million (CAD).
A discovery-oriented company with projects in Newfoundland and Labrador,
Sokoman Minerals Corp. (TSX-V: SIC, Forum) reported the execution of two property option agreements on behalf of the strategic alliance between the Company and
Benton Resources (TSX-V: BEX, Forum) to add additional mineral claims to the Grey River Gold Property.
Nevada Copper Corp. (TSX: NCU, Forum) gave an update regarding the ramp-up of the Underground Mine and development activities for the Open Pit project this week at its
Pumpkin Hollow Project in Nevada.
The company is in the process of safely completing the dike crossing, with all underground ventilation fans were installed and commissioned, as well as completed C5 testing of the processing plant for grind size and moisture. The company has also progressed its life-of-mine planning aimed at operating its underground mine at an ultimate production rate more than the originally contemplated 5,000 tons per day.
For previous editions of Buzz on the Bullboards:
click here.